The multi-centre, prospective, open-label, and randomised trial will enrol 40 subjects with diabetic foot ulcers. Credit: kirov1976 / Shutterstock.com.

Regenerative medicine company RION has dosed the first subject in the Phase IIa clinical trial of its purified exosome product (PEP) for the treatment of diabetic foot ulcers (DFUs).

The multi-centre, prospective, open-label and randomised trial is set to enrol 40 subjects.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It aims to assess the safety and efficacy of PEP when applied topically to DFUs.

Participants will be divided into a 1:1 ratio to receive two vials of PEP, in addition to standard care (SoC), and the other half will receive SoC alone.

Evaluating the comparative effectiveness of PEP treatment for up to 12 weekly applications versus SoC is the trial’s objective.

See Also:

PEP, which operates through a polyvalent mechanism, is crucial for tissue repair in DFU patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The product is a lyophilised powder made from human platelets and contains stabilised platelet-derived regenerative exosomes.

It is designed to encourage cell proliferation and new blood vessel formation, reduce inflammation, and offer cellular protection.

A successful outcome from the Phase IIa trial could lead to a pivotal study and eventually a biologics licence application for the product to treat DFUs.

RION co-founder Dr Atta Behfar said: “Dosing the first subject in the Phase II trial represents a key clinical advancement of our lead programme and is an important moment for both the company and the field of exosome science.

“With the Phase II effort, Rion has established key advances in exosome manufacturing and scaling, while cementing its commitment to revolutionising the treatment of chronic wounds. This pioneering exosome therapy is a testament to the potential of PEP to radically improve advanced wound care paradigms and patient outcomes.”